WASHINGTON: The Food and Drug Administration (FDA) has announced it will form a new advisory committee in order to address risk communications at the agency.The new committee will likely include professionals in healthcare communications, public relations, and social marketing industries, according to Sandy Walsh, public affairs specialist at the agency.
Though the announcement comes on the heels of the agency’s troubles with Glaxo Smith Kline’s Avandia, Walsh saad the formation of the committee is unrelated.
“We committed to doing a committee after the IOM [Institute of Medicine] had originally recommended it for drug issues, and we decided to expand it to all issues we regulate,” Walsh said.
The committee will make recommendations to the FDA on crafting risk and benefit messages as it relates to products regulated by the agency, as well as how to most effectively communicate product information to vulnerable audiences.
The agency will accept nominations for the 15-person committee for 45 days. Walsh says the FDA hopes the body will hold its first meeting in January 2008.